Alpine Immune Sciences Inc (ALPN)
64.97
+0.02
(+0.03%)
USD |
NASDAQ |
May 15, 16:00
64.97
0.00 (0.00%)
After-Hours: 18:51
Alpine Immune Sciences Enterprise Value: 4.150B for May 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 4.150B |
| May 13, 2024 | 4.150B |
| May 10, 2024 | 4.149B |
| May 09, 2024 | 4.141B |
| May 08, 2024 | 4.133B |
| May 07, 2024 | 4.128B |
| May 06, 2024 | 4.126B |
| May 03, 2024 | 4.126B |
| May 02, 2024 | 4.126B |
| May 01, 2024 | 3.930B |
| April 30, 2024 | 3.929B |
| April 29, 2024 | 3.936B |
| April 26, 2024 | 3.927B |
| April 25, 2024 | 3.931B |
| April 24, 2024 | 3.928B |
| April 23, 2024 | 3.926B |
| April 22, 2024 | 3.928B |
| April 19, 2024 | 3.926B |
| April 18, 2024 | 3.918B |
| April 17, 2024 | 3.920B |
| April 16, 2024 | 3.923B |
| April 15, 2024 | 3.918B |
| April 12, 2024 | 3.914B |
| April 11, 2024 | 3.916B |
| April 10, 2024 | 2.778B |
| Date | Value |
|---|---|
| April 09, 2024 | 2.247B |
| April 08, 2024 | 2.220B |
| April 05, 2024 | 1.983B |
| April 04, 2024 | 2.010B |
| April 03, 2024 | 2.193B |
| April 02, 2024 | 2.265B |
| April 01, 2024 | 2.331B |
| March 31, 2024 | 2.293B |
| March 28, 2024 | 2.271B |
| March 27, 2024 | 2.206B |
| March 26, 2024 | 2.127B |
| March 25, 2024 | 2.134B |
| March 22, 2024 | 2.251B |
| March 21, 2024 | 2.399B |
| March 20, 2024 | 2.310B |
| March 19, 2024 | 2.291B |
| March 18, 2024 | 1.998B |
| March 15, 2024 | 2.057B |
| March 14, 2024 | 2.025B |
| March 13, 2024 | 2.072B |
| March 12, 2024 | 2.062B |
| March 11, 2024 | 1.992B |
| March 08, 2024 | 2.028B |
| March 07, 2024 | 2.098B |
| March 06, 2024 | 2.199B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.816M
Minimum
Nov 12 2019
4.150B
Maximum
May 13 2024
307.03M
Average
124.68M
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 100.43B |
| Eliem Therapeutics Inc | 120.22M |
| Regeneron Pharmaceuticals Inc | 99.96B |
| Vera Therapeutics Inc | 1.882B |
| Eyenovia Inc | 38.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.92M |
| Revenue (Quarterly) | 7.032M |
| Total Expenses (Quarterly) | 29.73M |
| EPS Diluted (Quarterly) | -0.28 |
| Profit Margin (Quarterly) | -254.8% |
| Earnings Yield | -0.99% |
| Normalized Earnings Yield | -0.9851 |